WASHINGTON, Oct. 23, 2024—GO2 for Lung Cancer (GO2) will honor Novocure at its 19th annual “Simply the Best” Gala on Saturday, Nov. 2 at the Fairmont Hotel in San Francisco. 

Novocure will receive the 2024 “GO2 Excellence Award in Advancing Innovative Precision Medicine” for its leadership in developing novel cancer therapy approaches to treat people diagnosed with lung cancer.

“We are deeply honored to be recognized by GO2 for our commitment to advancing treatment options for lung cancer. The mission that drives our work at Novocure is to extend survival in aggressive forms of cancers and we recognize that many people living with lung cancer still need treatment options,” said Frank Leonard, EVP and president, Novocure Oncology. “We are proud to partner with GO2 in supporting lung cancer patients and their families, and we are dedicated to continuing our efforts developing treatment for this disease until there is a cure.”

Lung cancer is the single largest cancer killer. It claims more lives than breast, ovarian, and prostate cancers combined. More than 230,000 people will learn they have lung cancer this year, and 20% of those never smoked. The number of young women being diagnosed with lung cancer with no known risk factors is also increasing. Yet, if caught early, lung cancer is often treatable and even curable.

GO2 has a long history of providing one-on-one assistance, supportive connections, treatment information, and finding the best care close to home. It is also the place to go to learn about the latest research that increases survivorship.

“We are grateful to be able to honor Novocure with this award. The organization goes above and beyond to improve the lives of people with lung cancer,” said GO2 for Lung Cancer President and CEO Laurie Ambrose. “We recognize Novocure’s commitment to the needs of the lung cancer community and, through their groundbreaking treatments, are helping to increase survivorship.”